Empowering Life Against Cancer

We provide products for Indian manufacturers as well as from European countries.

Defying Cancer, Embracing Life

Gain access to top-quality EU-approved anticancer medications and expert support, ensuring optimal care and treatment efficacy for patients

Anticancer Products with Complaicne

Choose us for unparalleled access to EU-approved, GMP-compliant anticancer solutions, ensuring quality and efficacy. We offer comprehensive support and documentation for seamless procurement and regulatory compliance

List of Products

Product Name	Mfg. Site	Country Origin	Commercialization Status	Status
Carboplatin	EU GMP	EU Region	Dossier Ready - eCTD	Ready
Gemcitabine	EU GMP	EU Region	Dossier Ready - eCTD	Ready
Methotrexate	EU GMP	EU Region	Dossier Ready - eCTD	Ready
Irinotecan	EU GMP	EU Region	Dossier Ready - eCTD	Ready
Pemetrexed	EU GMP	EU Region	Dossier Ready - eCTD	Ready
Paclitaxel	EU GMP	EU Region	Dossier Ready - eCTD	Ready
Oxaliplatin	EU GMP	EU Region	Dossier Ready - eCTD	Ready
NAB Paclitaxel	EU GMP	EU Region	Dossier Ready - eCTD	Ready
Tacrolimus	EU GMP	EU Region	Final Validation underway	In Pipeline - 7 months to commercialization ready
Mycophenolate Mofetil	EU GMP	EU Region	Final Validation underway	In Pipeline - 7 months to commercialization ready
Mycophenolate Acid	EU GMP	EU Region	Final Validation underway	In Pipeline - 7 months to commercialization ready
Everolimus	EU GMP	EU Region	Final Validation underway	In Pipeline - 7 months to commercialization ready
Dabigatran	EU GMP	EU Region	Final Validation underway	In Pipeline - 7 months to commercialization ready
Budesonide	EU GMP	EU Region	Final Validation underway	In Pipeline - 7 months to commercialization ready
Heparin Bovine	SFDA	Saudi	Under approval	In Pipeline - 3 months to final approval
Enoxaparin	SFDA	Saudi	Under approval	In Pipeline - 3 months to final approval
Letrozole	EU GMP	EU Region	Final dossier ready for submission	7 months to PT CoPP, filing in Jan 2024 in PT
Imatinib	EU GMP	EU Region	Final dossier ready for submission	7 months to PT CoPP, filing in Jan 2024 in PT
Nilotinib	EU GMP	EU Region	BA/BE Study underway	10 months to market
Glimepiride & its combination	EU GMP	EU Region	BA/BE Study underway	10 months to market & 3 months to filing

Experience the pinnacle of excellence: Our rigorously developed anticancer molecule ensures top-tier quality and efficacy, meticulously crafted under stringent cGMP compliance